Clinical trials: Genome Instability
Advanced Solid Tumors, Colorectal Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214…
- Trial name
- NCT06004245
- Testing
- VVD-133214, Pembrolizumab, Bevacizumab
- Where
- 55 sites in United States, Australia and 9 more
- Volunteers
- 280 people
- Sponsor
- Vividion Therapeutics, Inc.
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes.
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Neoplasm, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT03428802
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Rutgers, The State University of New Jersey
POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability
Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
The purpose of this study is to determine if dMMR and/or POLE exonuclease domain mutant stage III colon cancer patients gain clinical benefit (i.e.
- Conditions
- POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer
- Trial name
- POLEM (NCT03827044)
- Testing
- Avelumab
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Carcinoma, Renal Cell, Head and Neck Neoplasm
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Carcinoma, Renal Cell, Head and Neck Neoplasm, Skin Neoplasms, Microsatellite Instability
- Trial name
- AcSé (NCT03012581)
- Testing
- Nivolumab
- Where
- France
- Volunteers
- 269 people
- Sponsor
- UNICANCER
Colorectal Neoplasms, Microsatellite Instability
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
In this study, MMRd metastatic colorectal cancer (mCRC) patients who failed standard therapies will undergo treatment with pembrolizumab, while RAS-extended mutated MMR-proficient mCRC patients will be tested for…
- Trial name
- ARETHUSA (NCT03519412)
- Testing
- temozolomide (induction),, pembrolizumab (treatment)
- Where
- 4 sites in Italy
- Volunteers
- 107 people
- Sponsor
- IFOM ETS - The AIRC Institute of Molecular Oncology
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC
Colon Adenocarcinoma, High-Frequency Microsatellite Instability
M7824 in Patients With Metastatic Colorectal Cancer or With Advanced Solid Tumors With Microsatellite Instability
This phase Ib/II trial studies how well anti-PD-L1/TGFbetaRII fusion protein M7824 (M7824) works in treating patients with colorectal cancer (or with other solid tumors with microsatellite instability) that has spread to other…
- Conditions
- Colon Adenocarcinoma, High-Frequency Microsatellite Instability, Metastatic Malignant Solid Neoplasm, Rectal Adenocarcinoma
- Trial name
- NCT03436563
- Testing
- Anti-PD-L1/TGFbetaRII Fusion Protein M7824
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer
A Study of Sovilnesib in Subjects With Ovarian Cancer
This is a phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of sovilnesib at different dose levels to establish the optimal dose of sovilnesib in subjects with selected advanced…
- Conditions
- High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
- Trial name
- NCT06084416
- Testing
- Sovilnesib
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Volastra Therapeutics, Inc.
Chromosomal Instability, Low Grade Dysplasia Oral Cavity
Diagnostics for the Treatment of Progressive Mucosal Lesions of the Oral Cavity: a Prospective Study
Despite improvements in therapy, head and neck carcinomas still have a poor prognosis with a 5-year survival of ~ 50%. Malignancies of the head and neck area are (almost) always preceded by precursor lesions.
- Conditions
- Chromosomal Instability, Low Grade Dysplasia Oral Cavity, Loss of Heterozygostiy, Fluorescence In Situ Hybridization
- Trial name
- NCT02238574
- Testing
- surgery, follow up
- Where
- Netherlands
- Sponsor
- Maastricht University Medical Center
Colorectal Neoplasms
Clinical and Molecular Characterization of Familial Microsatellite Stable Colorectal Cancer
Two major genetic pathways leading to colorectal carcinoma can well be distinguished; the 'suppressor pathway', which is characterized by inactivation of tumor-suppressor genes and the 'mutator pathway', which is characterized by…
- Trial name
- NCT00220246
- Where
- Netherlands
- Volunteers
- 130 people
- Sponsor
- Radboud University Medical Center
Longitudinal, Genomic Stability
Epidemiology and Overtime Genomic Evolution of Klebsiella Pneumoniae and Enterobacter Cloacae Complex (ECC) in Stools of ICU's Patients
Infections are one of the major threats for inpatients, even more for patients hospitalized in intensive care units (ICUs). They are responsible for an important increase of morbidity and mortality rates as well as a burst of…
- Conditions
- Longitudinal, Genomic Stability, Klebsiella Infections, Enterobacter Cloacae Infection
- Trial name
- NormandyKlebs (NCT07744321)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Caen
Bladder Cancer
Analyzing the Urine During BCG Instillation in Bladder Cancer Patients for Disease Followup
Bacillus Calmette-Guerin (BCG) has been extensively utilized in intravesical instillation therapy for patients with medium to high risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumor…
- Trial name
- NCT06153849
- Testing
- urine sample collection
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changhai Hospital
Endometrial Neoplasms, TP53 Gene Mutation
Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma
The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor tissue samples.
- Conditions
- Endometrial Neoplasms, TP53 Gene Mutation, Chromosomal Instability, Microsatellite Stable Endometrial Carcinoma
- Trial name
- NCT06521684
- Volunteers
- 110 people
- Sponsor
- Peking Union Medical College Hospital
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Colorectal Cancer, Colorectal Carcinoma
Microsatellite Instability in Colorectal Cancers
In this study, we aimed to identify the different histopathological features of tumors with microsatellite instability (MSI) compared to microsatellite stable (MSS) in patients who underwent surgery for colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Microsatellite Instability High, Microsatellite Instability Low
- Trial name
- MSI-CRC (NCT05162248)
- Testing
- Microsatellite instability analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 231 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Colorectal Cancer, Microsatellite Instability
Molecular Characteristics of Early-onset Compared With Late-onset Colorectal Cancer
The distribution rate of microsatellite instability-high (MSI-H) was significantly higher in early-onset colorectal cancer, and early-onset colorectal cancer has a specific mutational profile and relatively high programmed cell…
- Trial name
- NCT06238193
- Volunteers
- 11,344 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Recurrent Cervical Cancer, Nucleotide Variant
Genetic Mutation in Recurrent Cervical Cancer
Little is known about the characteristics of genetic mutation in recurrent cervical cancer. This study is to explore the targeted genetic mutations via a multi-gene panel, which consists of more than 500 hundred genes.
- Conditions
- Recurrent Cervical Cancer, Nucleotide Variant, Copy Number Variation, Insertion-deletion Variation
- Trial name
- NCT04191226
- Testing
- Multi-gene panel testing
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Lei Li